Relay Therapeutics Inc
Suletud
SektorTervishoid
14.82 4.15
Ülevaade
Aktsiahinna muutus
24h
Min
14.12
Max
15.04
Sissetulek | -18M -73M |
|---|---|
Müük | -4M 3M |
Aktsiakasum | -0.41 |
Kasumimarginaal | -2,443.033 |
Töötajad | 193 |
EBITDA | -20M -78M |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +61.52% upside |
Järgmine tulemuste avaldamine | 6. aug 2026 |
|---|
Turukapital | 442M 2.9B |
|---|---|
Eelmine avamishind | 10.67 |
Eelmine sulgemishind | 14.82 |
Relay Therapeutics Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Relay Therapeutics Inc Prognoos
Hinnasiht
By TipRanks
61.52% tõus
12 kuu keskmine prognoos
Keskmine 23 USD 61.52%
Kõrge 28 USD
Madal 18 USD
Põhineb 11 Wall Streeti analüütiku instrumendi Relay Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Relay Therapeutics Inc
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
